abstract |
Methods for using anti-LIVl antibodies, including drug conjugated anti-LIVl antibodies, to inhibit proliferation of a LIV-1 -expressing cell, as well as for the treatment of one or more diseases or disorders associated with LIV-1 -expressing cells (e.g., a LIV-1 -associated breast cancer), are provided. |